Lundoch Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$191K
- Investors
-
1
Lundoch General Information
Description
Developer of an AI-based diagnostic tool designed to provide a complete health system based on precision preventative treatment. The company offers a computer program that uses blood levels of follistatin in the blood as a biomarker for type diabetes prediction and risk assessment by inputting patented blood biomarker measurements, enabling doctors to detect early stages of diabetic risk before symptoms, to help minimize health complications related to diabetes.
Contact Information
Website
www.lundoch.comCorporate Office
- Medeon Science Park
- 205 12 Malmo
- Sweden
Corporate Office
- Medeon Science Park
- 205 12 Malmo
- Sweden
Lundoch Timeline
Lundoch Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 22-Nov-2024 | $191K | Completed | Generating Revenue | ||
| 2. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 1. Accelerator/Incubator | 23-Nov-2022 | Completed | Generating Revenue |
Lundoch Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares |
Lundoch Patents
Lundoch Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220252615-A1 | Method of using follistatin in type 2 diabetes risk prediction | Inactive | 28-Mar-2019 | ||
| US-20260266845-A1 | Method of using follistatin in type 2 diabetes risk prediction | Pending | 28-Mar-2019 | ||
| ES-2954164-T3 | Use of follistatin in predicting the risk of type 2 diabetes | Active | 28-Mar-2019 | ||
| AU-2020245775-A1 | Use of follistatin in type 2 diabetes risk prediction | Active | 28-Mar-2019 | ||
| AU-2020245775-B2 | Use of follistatin in type 2 diabetes risk prediction | Active | 28-Mar-2019 | G01N33/6893 |
Lundoch Signals
Lundoch Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Medeon Science Park | Accelerator/Incubator |
Lundoch FAQs
-
When was Lundoch founded?
Lundoch was founded in 2020.
-
Where is Lundoch headquartered?
Lundoch is headquartered in Malmo, Sweden.
-
What is the size of Lundoch?
Lundoch has 2 total employees.
-
What industry is Lundoch in?
Lundoch’s primary industry is Decision/Risk Analysis.
-
Is Lundoch a private or public company?
Lundoch is a Private company.
-
What is the current valuation of Lundoch?
The current valuation of Lundoch is .
-
What is Lundoch’s current revenue?
The current revenue for Lundoch is .
-
How much funding has Lundoch raised over time?
Lundoch has raised $191K.
-
Who are Lundoch’s investors?
Medeon Science Park has invested in Lundoch.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process